{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T04:07:37Z","timestamp":1791691657716,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012905","name":"Department of Science and Technology of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejps.2024.106779","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T11:40:40Z","timestamp":1713958840000},"page":"106779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Preparation and evaluation of inhalable S-allylmercapto-N-acetylcysteine and nintedanib co-loaded liposomes for pulmonary fibrosis"],"prefix":"10.1016","volume":"197","author":[{"given":"Qinxiu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongzheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8679-3130","authenticated-orcid":false,"given":"Zhongxi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejps.2024.106779_bib0049","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/17476348.2018.1513332","article-title":"Novel management strategies for idiopathic pulmonary fibrosis","volume":"12","author":"Ahmad","year":"2018","journal-title":"Expert. Rev. Respir. Med."},{"issue":"1","key":"10.1016\/j.ejps.2024.106779_bib0001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMcibr1811639","article-title":"Revealing the secrets of idiopathic pulmonary fibrosis","volume":"380","author":"Albert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejps.2024.106779_bib0016","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pulmoe.2018.06.003","article-title":"Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: real-life experience in an Italian referral centre","volume":"25","author":"Bargagli","year":"2019","journal-title":"Pulmonology"},{"issue":"2","key":"10.1016\/j.ejps.2024.106779_bib0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2011.12.004","article-title":"Controlled pulmonary drug and gene delivery using polymeric nano-carriers","volume":"161","author":"Beck-Broichsitter","year":"2012","journal-title":"J. Controlled Release"},{"issue":"2","key":"10.1016\/j.ejps.2024.106779_bib0012","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00606662","article-title":"Pharmacokinetics of N-acetylcysteine in man","volume":"31","author":"Borgstrm","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejps.2024.106779_bib0029","doi-asserted-by":"crossref","first-page":"11883","DOI":"10.1007\/s13277-016-5038-6","article-title":"Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation","volume":"37","author":"Cai","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejps.2024.106779_bib0018","first-page":"159","article-title":"Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a 24-month assessment","author":"Cerri","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejps.2024.106779_bib0020","series-title":"Drugs","article-title":"Nintedanib: first global approval","author":"Cormack","year":"2015"},{"key":"10.1016\/j.ejps.2024.106779_bib0025","series-title":"Galectin-3 As a Novel Biomarker For Disease Diagnosis and a Target For Therapy (Review)","author":"Dong","year":"2017"},{"issue":"2014","key":"10.1016\/j.ejps.2024.106779_bib0052","first-page":"2071","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Du, Bois","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2024.106779_bib0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbrc.2021.05.047","article-title":"S -Allylmercapto -N -acetylcysteine ameliorates elastase-induced chronic obstructive pulmonary disease in mice via regulating autophagy","volume":"562","author":"Dz","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejps.2024.106779_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2018.03.005","article-title":"The influence of surface active L-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders","author":"Eedara","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejps.2024.106779_bib0056","first-page":"767","article-title":"Pegylated polyaspartamide\u2013polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus","volume":"17","author":"Emanuela, Fabiola","year":"2016","journal-title":"Macromolecules"},{"key":"10.1016\/j.ejps.2024.106779_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2021.03.017","article-title":"Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment","volume":"164","author":"Ghumman","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.ejps.2024.106779_bib0017","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2024.106779_bib0019","first-page":"50","article-title":"Endotype\u2013phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease","author":"Hoffmann-Vold","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejps.2024.106779_bib0058","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.ejps.2024.106779_bib0040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.freeradbiomed.2011.01.028","article-title":"S-allylmercapto-N-acetylcysteine up-regulates cellular glutathione and protects vascular endothelial cells from oxidative stress","volume":"50","author":"Izigov","year":"2011","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejps.2024.106779_bib0044","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2019.08.017","article-title":"Phospholipid-modified poly(lactide- co -glycolide) microparticles for tuning the interaction with alveolar macrophages: in vitro and in vivo assessment","volume":"143","author":"J","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2024.106779_bib0046","article-title":"TGF-\u03b21 Signaling and Tissue Fibrosis","author":"Kim","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ejps.2024.106779_bib0033","first-page":"52","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial","author":"Kolb","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"18","key":"10.1016\/j.ejps.2024.106779_bib0050","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2024.106779_bib0054","series-title":"Proceedings of the National Academy of Sciences","first-page":"1482","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007"},{"issue":"2008","key":"10.1016\/j.ejps.2024.106779_bib0009","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0084-3873(08)79224-1","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis","author":"Lewis","year":"2008","journal-title":"Yearbook Med."},{"issue":"46","key":"10.1016\/j.ejps.2024.106779_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202008379","article-title":"Mediated drug release from nanovehicles by black phosphorus quantum dots for efficient therapy of chronic obstructive pulmonary disease","volume":"59","author":"Li","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejps.2024.106779_bib0036","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2019.08.017","article-title":"Phospholipid-modified poly(lactide-co-glycolide) microparticles for tuning the interaction with alveolar macrophages: in vitro and in vivo assessment","volume":"143","author":"Li","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"348","key":"10.1016\/j.ejps.2024.106779_bib0014","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2022.05.039","article-title":"Novel drug delivery systems and disease models for pulmonary fibrosis","author":"Li","year":"2022","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejps.2024.106779_bib0010","article-title":"Influence of age on wound healing and fibrosis","author":"Maria, Kapetanaki","year":"2012","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.ejps.2024.106779_bib0027","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.celrep.2015.02.012","article-title":"Acts as a toll-like receptor 4 ligand and contributes to microglial activation","volume":"10","year":"2015","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.ejps.2024.106779_bib0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/pharmaceutics6020333","article-title":"Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers","volume":"6","author":"Muralidharan","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106779_bib0053","first-page":"63","article-title":"Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis","author":"Mws","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106779_bib0015","first-page":"2","article-title":"Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine","author":"Myllarniemi","year":"2015","journal-title":"Eur. Clin. Respir. J."},{"issue":"7","key":"10.1016\/j.ejps.2024.106779_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-016-1911-7","article-title":"Liposomal aerosols of Nitric Oxide (NO) donor as a long-acting substitute for the ultra-short-acting inhaled NO in the treatment of PAH","volume":"33","author":"Nahar","year":"2016","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejps.2024.106779_bib0004","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI60323","article-title":"Pulmonary fibrosis: patterns and perpetrators","volume":"122","author":"Noble","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejps.2024.106779_bib0013","article-title":"Pathogenesis of idiopathic pulmonary fibrosis","author":"Paul","year":"2014","journal-title":"Ann. Rev. Pathol. Mech. Dis."},{"issue":"3","key":"10.1016\/j.ejps.2024.106779_bib0002","first-page":"179","article-title":"Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders","author":"Piera","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejps.2024.106779_bib0042","first-page":"7b14992","article-title":"Mucus and cell-penetrating nanoparticles embedded in nano-into-micro formulations for pulmonary delivery of ivacaftor in patients with cystic fibrosis","author":"Porsio","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"5","key":"10.1016\/j.ejps.2024.106779_bib0021","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00408-019-00260-1","article-title":"Self-reported gastrointestinal side effects of antifibrotic drugs in dutch idiopathic pulmonary fibrosis patients","volume":"197","author":"Proesmans","year":"2019","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.ejps.2024.106779_bib0032","article-title":"Combination therapy with pirfenidone plus prednisolone ameliorates paraquat-induced pulmonary fibrosis","volume":"41","author":"Rasooli","year":"2018","journal-title":"Inflammation"},{"issue":"12","key":"10.1016\/j.ejps.2024.106779_bib0051","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2024.106779_bib0045","article-title":"Bleomycin revisited: towards a more representative model of IPF?","author":"Scotton","year":"2010","journal-title":"Am. J. Physiol."},{"issue":"17","key":"10.1016\/j.ejps.2024.106779_bib0041","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/jf202082f","article-title":"Nonvolatile S-alk(en)ylthio-l-cysteine derivatives in fresh onion (Allium cepa L. cultivar)","volume":"59","author":"Starkenmann","year":"2011","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejps.2024.106779_bib0034","first-page":"242","article-title":"Combined intervention with N-acetylcysteine and desipramine alleviated silicosis development by regulating the Nrf2\/HO-1 and ASMase\/ceramide signaling pathways","author":"Tang","year":"2022","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"10.1016\/j.ejps.2024.106779_bib0006","series-title":"Proceedings of the American Thoracic Society","article-title":"Is idiopathic pulmonary fibrosis an environmental disease?","author":"Taskar","year":"2006"},{"issue":"105","key":"10.1016\/j.ejps.2024.106779_bib0007","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.micpath.2017.02.023","article-title":"Role of human bocavirus in idiopathic pulmonary fibrosis","author":"Windisch","year":"2017","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.ejps.2024.106779_bib0008","article-title":"Exposure to ambient particulate matter is associated with accelerated functional decline in idiopathic pulmonary fibrosis","author":"Winterbottom","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ejps.2024.106779_bib0048","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12885-018-4461-z","article-title":"Galectin-3 activates TLR4\/NF-\u03baB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression","volume":"18","author":"Wu","year":"2018","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ejps.2024.106779_bib0057","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of surface Polyethylene Glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"issue":"13","key":"10.1016\/j.ejps.2024.106779_bib0026","first-page":"93","article-title":"Expression of galectin-3 modulates T-cell growth and apoptosis","author":"Yang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejps.2024.106779_bib0011","doi-asserted-by":"crossref","unstructured":"Yin Q., Strong M.J., Zhuang Y., et al. Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq. 2020.","DOI":"10.21203\/rs.2.11953\/v3"},{"key":"10.1016\/j.ejps.2024.106779_bib0003","first-page":"126","article-title":"The extracellular matrix and mechanotransduction in pulmonary fibrosis","author":"Zd","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejps.2024.106779_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2019.02.003","article-title":"Enhanced cellular polysulfides negatively regulate TLR4 signaling and mitigate lethal endotoxin shock","author":"Zhang","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejps.2024.106779_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114018","article-title":"S-allylmercapto-N-acetylcysteine ameliorates pulmonary fibrosis in mice via Nrf2 pathway activation and NF-\u03baB, TGF-\u03b21\/Smad2\/3 pathway suppression","volume":"157","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejps.2024.106779_bib0005","first-page":"14","article-title":"Dissecting the underlying pharmaceutical mechanism of Danggui Buxue decoction acting on idiopathic pulmonary fibrosis with network pharmacology","volume":"5","author":"Zhao","year":"2020","journal-title":"TMR"},{"key":"10.1016\/j.ejps.2024.106779_bib0037","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejpb.2022.01.009","article-title":"Elucidating inhaled liposome surface charge on its interaction with biological barriers in the lung","volume":"172","author":"Zhao","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10159","key":"10.1016\/j.ejps.2024.106779_bib0022","article-title":"Preliminary therapeutic and mechanistic evaluation of S-allylmercapto-N-acetylcysteine in the treatment of pulmonary emphysema","volume":"98","author":"Zheng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejps.2024.106779_bib0024","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbrc.2021.05.047","article-title":"S-Allylmercapto-N-acetylcysteine ameliorates elastase-induced chronic obstructive pulmonary disease in mice via regulating autophagy","volume":"562","author":"Zheng","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejps.2024.106779_bib0028","article-title":"Galectin-3 activates TLR4\/NF-\u03baB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression","author":"Zhou","year":"2018","journal-title":"BioMed Central"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T04:08:30Z","timestamp":1715054910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":58,"alternative-id":["S0928098724000903"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106779","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation and evaluation of inhalable S-allylmercapto-N-acetylcysteine and nintedanib co-loaded liposomes for pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106779"}}